On December 6, the "Blue Book of the Internationalization of China's Pharmaceutical Industry (2023)" (hereinafter referred to as the "Blue Book") was officially released at the tenth Council of the seventh session of the China Medical Insurance Chamber of Commerce.
Blue Book release Panorama
Wang Maochun, vice president of the Chamber of Commerce of Medical Insurance, presided over the release ceremony of the "Blue Book". He introduced that the 2023 version of the "Blue Book" was jointly compiled by the China Chamber of Commerce for Import and Export of Pharmaceutical and Health Products, the United Nations Industrial Development Organization Investment and Technology Promotion Office (Beijing, China), and the China Drug Regulatory and Administration Research Society. In particular, leaders of the Department of Science and Technology and International Cooperation of the National Medical Products Administration and the ICH Work Office were invited to write a theme article on regulatory policy, and the United Nations Children's Fund (UNICEF) was specially invited to provide a special article in the new "International procurement" article.
In addition, domestic and foreign research institutions and industry organizations such as IQVIA, Pharmaprojects, Intertek Group, Zhejiang Pharmaceutical Regulatory and Industrial Development Research Association, Shenzhen Life Science and Biotechnology Association, and Aishekang (Shanghai) Health Consulting Co., Ltd. have written special articles from their own perspectives. Leading international enterprises such as Huahai Pharmaceutical, Sansheng Pharmaceutical, Sinovac Pharmaceutical, Kelun Pharmaceutical, Legendary Biology, Jiuzhou Pharmaceutical, Lianying Medical and Zhende Medical shared their development experience.
Vice President Wang Maochun presided over the release ceremony of the Blue Book
At the launch ceremony, Mr. Wu Yabin, Director of the Office of Investment and Technology Promotion of the United Nations Industrial Development Organization (Beijing, China), and Mr. Zhang Wei, President of the China Drug Regulatory and Administration Research Society, delivered a video address respectively.
Director Wu Yabin said that 2023 is the first year of global recovery after the epidemic, and with the continuous changes in the international political and economic situation, the development pattern of the global pharmaceutical and health industry is also facing profound adjustment and reform. In the face of the new situation, China's pharmaceutical industry adheres to innovation-driven progress, maintains the stability of the toughness of the pharmaceutical industry chain, and accelerates the realization of high-quality development. At the same time, China has actively promoted international exchanges and cooperation in the field of medicine and health, helped the international community better prevent and respond to global health crises, and jointly built a more resilient and sustainable global health system. The "Blue Book" provides valuable experience for Chinese pharmaceutical enterprises to sail to the sea, and contributes Chinese wisdom to the sustainable development of the global pharmaceutical industry.
President Zhang Wei said that after years of efforts, the international development of China's pharmaceutical industry has achieved good results, pharmaceutical trade and investment, overseas clinical trials, overseas authorization transactions and other aspects are developing steadily, and innovative drugs continue to be approved for listing in developed markets such as Europe and the United States. At the same time, the internationalization level of China's drug supervision is also constantly improving, and constantly promoting supervision and international standards, and creating a good international environment for the high-quality development of the industry is one of the important responsibilities and missions of China's drug administration. Internationalization is not achieved overnight, and it requires the efforts of enterprises, industries and governments to jointly promote the internationalization of China's pharmaceutical industry. He hopes that the "Blue Book" can become better and better and become a "guide" for the international development of China's pharmaceutical industry.
Subsequently, Zhou Hui, President of the Medical Insurance Chamber of Commerce, Ban Yan, Vice president of the Medical Insurance Chamber of Commerce and Vice president of Zhongninghua Group, Li Ning, honorary Vice president of the Medical Insurance Chamber and vice president of BGI, Wang Jun, chairman of Huapao International, Chen Xi, Senior Vice President of Jinsilui Biology, Wang Jishu, Director of Public Affairs of Mindray Medical International, Luo Yuanyuan, sales director of Huahai Pharmaceutical, Zhao Yizhou, deputy director of the Belt and Road Division of Kanghong Pharmaceutical and other guests took the stage to jointly launch the release ceremony of the "Blue Book".
Blue Book officially released
The 2023 edition of the Blue Book is divided into 9 chapters, comprehensively combing the context of the international development of China's pharmaceutical industry, summing up excellent development experience, and putting forward suggestions for future development.
The regulatory policy chapter comprehensively introduces the latest progress and trends in the internationalization of China's drug regulation. The State Food and Drug Administration has continuously created a new situation in international cooperation in drug regulation, and the internationalization level and international influence of China's drug regulation have been continuously improved. The achievements and latest progress of the State Food and Drug Administration since joining ICH were summarized.
Industry Development reviews and outlooks global pharmaceutical spending in 2023, including the impact of COVID-19 on drug use, prospects and historical drivers of drug use, spending and growth in major countries and regions, and key treatment areas. Global pharmaceutical R&D trends in early 2023 are analyzed to assess industry trends by reviewing R&D production systems by company, therapeutic area, disease, target, and drug type.
The foreign trade chapter comprehensively summarizes the import and export situation and international development trend of medical and health products and subdivided Chinese medicine, Western medicine, medical devices, dietary nutritional supplements in 2022, and analyzes the situation of trade friction in the pharmaceutical industry in 2022.
International Registration reviewed the European and American drug regulatory regulations, guidelines and ICH guidelines update, European and American drug registration situation, and put forward relevant suggestions.
The regional development part summarizes the international development of pharmaceutical industry in Zhejiang Province, and the problems and difficulties it faces. The present situation of the international development of pharmaceutical industry in Shenzhen and the good ecological environment created for the international development of biomedicine industry were introduced.
The chapter on Multilateral cooperation introduces the UN's efforts to promote universal health coverage through improving pandemic preparedness, improving digital health care mechanisms, and deepening cooperation with China. How the United Nations Industrial Development Organization helps the pharmaceutical industry innovation in developing countries, and the United Nations Industrial Development Organization Investment and Technology Promotion Network to promote the development of the pharmaceutical industry chain measures.
This article reviews the achievements made by Chinese pharmaceutical and health enterprises in "going out" in key regional markets along the "Belt and Road" in the past decade in ASEAN, the Middle East, Central and Eastern Europe, Africa, Latin America, etc., and looks forward to the future, and makes an in-depth analysis of the African and Southeast Asian markets.
The International Procurement section describes the procurement of goods and services carried out by UNICEF and shares details about the procurement of medicines by UNICEF; A comprehensive analysis of the United Nations public procurement in 2022.
Corporate case studies share the development experience of leading international enterprises.
Blue book stereo
How to order Blue Book:
Scan the QR code below to buy directly
Contact person
Ms. Wu and Mr. Wu 010-58036286/80
Reading: https://jinshuju.net/f/ROOQ9d